이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Smith & Nephew 관리

관리 기준 확인 3/4

Smith & Nephew's CEO는 Deepak Nath, Apr2022 에 임명되었습니다 의 임기는 2.17 년입니다. 총 연간 보상은 $ 4.66M, 32.5% 로 구성됩니다. 32.5% 급여 및 67.5% 보너스(회사 주식 및 옵션 포함). 는 $ 2.03M 가치에 해당하는 회사 주식의 0.018% 직접 소유합니다. 2.03M. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 2.3 년입니다.

주요 정보

Deepak Nath

최고 경영자

US$4.7m

총 보상

CEO 급여 비율	32.5%
CEO 임기	2.4yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	2.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Deepak Nath 의 보수는 Smith & Nephew 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 29 2024	n/a	n/a	US$305m
Mar 29 2024	n/a	n/a	US$284m
Dec 31 2023	US$5m	US$2m	US$263m
Sep 30 2023	n/a	n/a	US$241m
Jul 01 2023	n/a	n/a	US$218m
Apr 01 2023	n/a	n/a	US$221m
Dec 31 2022	US$6m	US$1m	US$223m

보상 대 시장: Deepak 의 총 보상 ($USD 4.66M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 13.50M ).

보상과 수익: Deepak 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Deepak Nath (52 yo)

2.4yrs

테뉴어

US$4,658,252

보상

Dr. Deepak S. Nath, Ph D., serves as Director at Smith & Nephew plc since April 1, 2022. He served as Head of Diagnostics at Siemens Healthineers AG since 2021 until 2022 and served as its President of Lab...

리더십 팀

이름	위치	테뉴어	보상	소유권
Deepak Nath	CEO & Director	2.4yrs	US$4.66m	0.018% $ 2.5m
John Rogers	CFO & Executive Director	less than a year	데이터 없음	데이터 없음
Paul Connolly	President of Global Operations	2.9yrs	데이터 없음	0.0037% $ 502.8k
Andrew Swift	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Helen Barraclough	Group General Counsel & Company Secretary	2.7yrs	데이터 없음	0.0044% $ 600.6k
Alison Parkes	Chief Compliance Officer & Compliance APAC	2.7yrs	데이터 없음	0.00036% $ 48.9k
Joe Metzger	Senior Vice President of Marketing Services & Communications	13.7yrs	데이터 없음	데이터 없음
Philip Cowdy	Chief Corporate Development & Corporate Affairs Officer	no data	데이터 없음	0.0066% $ 902.3k
Elga Lohler	Chief Human Resources Officer	8.8yrs	데이터 없음	0.019% $ 2.6m
Vasant Padmanabhan	President of Research & Development and Ear	8.1yrs	데이터 없음	0.014% $ 1.9m
Steve Kane	Head of Human Resources for the US	no data	데이터 없음	데이터 없음
Ian Melling	Senior Vice President of Group Finance	no data	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: SNN 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Deepak Nath	CEO & Director	2.4yrs	US$4.66m	0.018% $ 2.5m
John Rogers	CFO & Executive Director	less than a year	데이터 없음	데이터 없음
Marc Owen	Senior Independent Director	6.9yrs	US$206.78k	0.0020% $ 269.1k
Simon Lowth	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
Rupert Soames	Independent Non-Executive Chairman	1.4yrs	US$180.82k	0.0016% $ 224.2k
Angela Risley	Independent Non-Executive Director	7yrs	US$118.56k	0.00069% $ 93.8k
Changzheng Ma	Independent Non-Executive Director	3.6yrs	US$171.78k	0.00024% $ 32.6k
Jeremy Maiden	Independent Non-Executive Director	less than a year	US$26.24k	0.00011% $ 14.9k
Katarzyna Mazur-Hofsaess	Independent Non-Executive Director	3.8yrs	US$93.06k	0.00021% $ 28.5k
Joanna Hallas	Independent Non-Executive Director	2.6yrs	US$93.06k	0.00065% $ 88.3k
Robert White	Independent Non-Executive Director	4.3yrs	US$164.78k	0.0010% $ 140.0k

2.6yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: SNN 의 이사회는 경험(평균 재직 기간 2.3 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Smith & Nephew 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew plc Announces Board Changes

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Recent updates

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew Delivering On Its Turnaround Promise

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Smith & Nephew: Work To Be Done But Still Long-Term Potential

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Smith & Nephew: Orthopedics Growth Continues To Drive Sales Forward

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Smith & Nephew Getting More Interesting As A Contrarian Idea

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc Increases Revenue Guidance for 2023

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Smith & Nephew: Entering New Markets But Growth Is Slow Still

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Smith & Nephew reports FY earnings; initiates FY23 guidance

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Smith & Nephew: Potential Only Has Value If You Can Execute

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Smith & Nephew: Still A Buy Despite Short-Term Challenges

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith &amp; Nephew 1H 2022 Earnings Preview

Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care

Smith+Nephew launches app Wound Compass to help reduce variation in wound care

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Announces Executive Changes

Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation

Smith & Nephew: Fair Price For An Attractive Medical Devices Supplier

Smith+Nephew Announces New Study Showing GRAFIX™ Membrane Cut the Rate of Diabetic Foot Ulcer Recurrence in Half Compared to Leading Competitors

Smith & Nephew plc, Annual General Meeting, Apr 13, 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Smith+Nephew Expands Next-Generation Handheld Robotic-Assisted CORI™ Surgical System into Total Hip Arthroplasty with RI.HIP NAVIGATION

Smith & Nephew: Valuation Looking More Attractive

Smith+Nephew Announces New Indications for Use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems

Smith & Nephew plc (LSE:SN.) acquired Engage Surgical.

Smith & Nephew plc (LSE:SN.) announces an Equity Buyback for $300 million worth of its shares.

Smith+Nephew Launches Real Intelligence and CORI Surgical System and Next Generation Handheld Robotics Platform in Canada

Smith+Nephew Launches CORI Handheld Robotics

Smith & Nephew Is A Premium Brand That Should Deliver Something Special

Smith & Nephew Leveraged To Post-Pandemic Normalization And Self-Help

Smith+Nephew Introduces Pioneering New Technologies for Its Journey II Total Knee Arthroplasty Portfolio

Smith+Nephew Announces Launch of WEREWOLF FASTSEAL 6.0 Hemostasis Wand

Smith+Nephew Announces Study Results Showing Patients Treated with Just its REGENETEN Bioinductive Implant for Partial-Thickness Rotator Cuff Tears

Smith & Nephew plc: Improving Performance Reflected In Price

Smith+Nephew Launches ARIA Home PT, a Remote Physical Therapy Solution

Smith & Nephew plc Provides Revenue Guidance for the Full Year 2021

Smith+Nephew's ALLEVYN™ LIFE Foam Dressings Halved Change Frequency, Significantly Reduced Cost and Improved Treatment Satisfaction in Real-World Study

Net Health Adds Smith+Nephew's RENASYS GO Negative Pressure Wound Therapy System to Net Health® Wound Care Connections Lineup

Smith & Nephew plc, Annual General Meeting, Apr 14, 2021

Smith & Nephew 1H 2022 Earnings Preview